Current view and outcome of ITI therapy - A change over time?

Thrombosis Research

Volumn 148, Issue , 2016, Pages 38-44

  Holstein, K ^a   Batorova, A ^b   Carvalho, M ^c   Fijnvandraat, K ^d   Holme, P ^e   Kavakli, K ^f   Lambert, T ^g   Rocino, A ^h   Jimenez Yuste V ⁱ   Astermark, J ^j  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c Centro Hospitalar Universitário de São João   (Portugal)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f EGE UNIVERSITY   (Turkey)

^g BICÊTRE HOSPITAL   (France)

^h Ospedale San Giovanni Bosco   (Italy)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Haemophilia; Immune tolerance induction; Immunosuppression; Inhibitors; ITI regimens

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MYCOPHENOLATE MOFETIL; RITUXIMAB; STEROID; VINCRISTINE;

ANAPHYLAXIS; ARTICLE; CLINICAL OUTCOME; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EUROPE; HEALTH CARE SURVEY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; MAJOR CLINICAL STUDY; NEPHROTIC SYNDROME; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; SEPSIS; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT RESPONSE; ADOLESCENT; ADULT; ADVERSE EFFECTS; CHILD; FEMALE; IMMUNOLOGY; MALE; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; EUROPE; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84992153352     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.10.015     Document Type: Article

References (63)

1. [1] Wight, J., Paisley, S., The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:4 (2003), 18–35.
2. [2] Key, N.S., Inhibitors in congenital coagulation disorders. Br. J. Haematol. 127 (2004), 379–391.
3. [3] Eckhardt, C.L., van Velzen, A.S., Peters, M., et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere haemophilia A. Blood 122:11 (2013), 1954–1962, 10.1182/blood-2013-02-483263.
4. [4] Astermark, J., FVIII inhibitors: pathogenesis and avoidance. Blood 125:13 (Mar. 26 2015), 2045–2051, 10.1182/blood-2014-08-535328 (Epub 2015 Feb 23 ahead of print).
5. [5] Alvarez, T., Soto, I., Astermark, J., Non-genetic risk factors and their influence on the management of patients in the clinic. Eur. J. Haematol. 94:Suppl. 77 (2015), 2–6.
6. [6] Astermark, J., Treatment of bleeding inhibitor patients. Semin. Thromb. Haemost. 29 (2003), 77–86.
7. [7] DiMichele, D., Rivard, G., Hay, C., Antunes, S., Inhibitors in haemophilia: clinical aspects. Haemophilia 10 (2004), 140–145.
8. [8] Brackmann, H.H., Oldenburg, J., Schwaab, R., Immune tolerance of factor VIII inhibitors – twenty years' ‘bonn protocol’. Vox Sang. 70:Suppl. 1 (1996), 30–35.
9. [9] Mauser-Bunschoten, E.P., Nieuwenhuis, H.K., Roosendaal, G., van den Berg, H.M., Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 86:3 (1995), 983–988.
10. [10] Frieburghaus, C., Berntorp, E., Ekman, M., Gunnarsson, M., Kjellberg, B., Nilsson, I.M., Tolerance induction using the Malmö treatment model 1982–1995. Haemophilia 5:1 (1999), 32–39.
11. [11] Astermark, J., Morado, M., Rocino, A., et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 12 (2006), 363–371.
12. [12] Hay, C.R.M., DiMichele, D., On behalf of the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 119:6 (2012), 1335–1344.
13. [13] Mathias, M., Liesner, R., Hann, I., Khair, K., Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience. Haemophilia 11 (2005), 340–345.
14. [14] Barnes, C., Rivard, G.E., Poon, M.-C., et al. Canadian multi-institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT. Haemophilia 12 (2006), 1–6.
15. [15] Valentino, L.A., Recht, M., Dipaola, J., et al. Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A. Haemophilia 15 (2009), 718–726.
16. [16] Ter Avest, P.C., Fischer, K., Gouw, S.C., Van Dijk, K., Mauser-Bunschoten, E.P., Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda units. Haemophilia 16 (2010), 71–79.
17. [17] Callaghan, M.U., Rajpurkar, M., Chitlur, M., Warrier, I., Lusher, J., Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?. Haemophilia 17 (2010), 483–489.
18. [18] Lin, P.-C., Liao, Y.-M., Tsai, S.-P., Chang, T.-T., Immune tolerance induction therapy for patients with haemophilia A and FVIII inhibitors particularly using low-dose regimens. Pediatr. Blood Cancer 57 (2011), 1029–1033.
19. [19] Ryu, J.E., Park, Y.S., Yoo, K.Y., Lee, K.D., Choi, Y.M., Immune tolerance induction in patients with severe haemophilia A with inhibitors. Blood Res. 50:4 (2015), 248–253.
20. [20] Nakar, C., Manco-Johnson, M.J., Lail, A., Donfield, S., Maahs, J., Chong, Y., Blades, T., Shapiro, A., Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two US centres. Haemophilia 21:3 (2015 May), 365–373.
21. [21] Batorova, A., Jankovicova, D., Morongova, A., et al. Inhibitors in severe haemophilia A: 25-year experience in Slovakia. Semin. Thromb. Hemost. 42 (2016), 550–562.
22. [22] Orsini, F., Rotschild, C., Beurrier, P., Faradji, A., Goudemand, J., Polack, B., Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 90 (2005), 1288–1290.
23. [23] Gringeri, A., Musso, R., Mazzucconi, M.G., et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of poor response. Haemophilia 13 (2007), 373–379.
24. [24] Unuvar, A., Kavakli, K., Baytan, B., et al. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors. Haemophilia 14 (2008), 315–322.
25. [25] Greninger, D.A., Saint-Remy, J.M., Jacquemin, M., Benhida, A., Dimichele, D.M., The use of factor VII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 14 (2008), 295–302.
26. [26] Platkouki, H., Pergantou, H., Xafaki, P., Komitopoulou, A., Aronis, S., Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor. Haemophilia 15 (2009), 617–619.
27. [27] Bidlingmaier, C., Kurnik, K., Escuriola-Ettinghausen, C., et al. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemocetin SDH®) in 14 patients with severe haemophilia A. Haemophilia 17 (2011), e831–e848.
28. [28] Kreuz, W., Escuriola Ettingshausen, C., Vdovin, V., et al. ObsITI study group; ObsITI committee. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia 22:1 (2016), 87–95.
29. [29] Robertson, J.D., Higgins, P., Price, J., Dunkley, S., Barrese, G., Curtin, J., Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study. Thromb. Res. 134:5 (2014), 1046–1051.
30. [30] Van Velzen, A.S., Peters, M., van der Bom, J.G., Fijnvandraat, K., Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. Br. J. Haematol., May 16 2014, 10.1111/bjh.12942.
31. [31] Kurth, M., Puetz, J., Kouides, P., et al. The use of single von Willebrand factor-containing, plasma-derived FVIII product in haemophilia A immune tolerance induction: the US experience. J. Thromb. Haemost. 9 (2011), 2229–2234.
32. [32] Collins, P.W., Mathias, M., Hanley, J., et al. Rituximab and immune tolerance in severe haemophilia A: a consecutive national cohort. J. Thromb. Haemost. 7 (2009), 787–794.
33. [33] Leissinger, C., Josephson, C.D., Granger, S., et al. Rituximab for treatment of inhibitors in haemophilia A. A Phase II Study. Thromb. Haemost. 112:3 (2014), 445–458.
34. [34] Shakathkumar, A., Lillicrap, D., Blanchette, V.S., et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild haemophilia A. J. Thromb. Haemost. 1 (2003), 1228–1236.
35. 618➔Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br. J. Haematol. 117 (2002), 136–140.
36. [36] Kobrinsky, N.L., Sjolander, D.E., Moser, D.K., Stegman, D.A., Ablation of haemophilic inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance. Am. J. Hematol. 76 (2004), 180–184.
37. [37] Dunkley, S., Kershaw, G., Young, G., et al. Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol. Haemophilia 12 (2006), 663–667.
38. [38] Carcao, N., St Louis, J., Poon, M.-C., et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 12 (2006), 7–18.
39. [39] Kempton, C.L., Allen, G., Hord, J., et al. Eradiation of factor VIII inhibitors in patients with mild and moderate haemophilia A. Am. J. Hematol. 87:9 (2012), 933–936.
40. [40] Van Veltzen, A.S., Eckhardt, C.L., Hart DP; et al for the INSIGHT study group inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb. Haemost. 114 (2015), 46–55.
41. [41] DiMichele, D.M., Kroner, B.L., The North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb. Haemost. 87 (2002), 52–57.
42. [42] DiMichele, D., The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 15:1 (2009), 320–328, 10.1111/j.1365-2516.2008.01880.x.
43. [43] Chitlur, M., Warrier, I., Rajpurkar, M., Lusher, J., Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997–2006). Haemophilia 15 (2009), 1027–1032.
44. [44] Castaman, G., Bonette, E., Messina, M., et al. Italian Association of Haemophilia Centres. Inhibitors in haemophilia B: the Italian experience. Haemophilia 19:5 (2013), 686–690, 10.1111/hae.12158.
45. [45] Klukowska, A., Laguna, P., Waleszkiewicz-Majewska, B., et al. Successful immune tolerance induction in two boys with haemophilia B and inhibitory antibodies. Haemophilia 18 (2012), e60–e87.
46. [46] Cross, D.C.A., Van den Berg, H.M., Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia 13 (2007), 111–114.
47. [47] Soto, I., Vicente, M., Corte, J.R., Urgelles, M.F., Pinto, C.R., Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor. Haemophilia 10 (2004), 401–404.
48. [48] Suzuki, N., Watanabe, J., Kudoh, T., et al. Successful induction of immune tolerance in a patient with haemophilia B with inhibitor. Haemophilia 9 (2003), 340–342.
49. [49] Barnes, C., Davis, A., Furmedge, J., Egan, B., Donnan, L., Monagle, P., Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX. Haemophilia 16 (2010), 840–842.
50. [50] Beutel, K., Hauch, H., Rischewski, J., Kordes, U., Scheppenheim, J., Scheppenheim, R., ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie 29 (2009), 155–157.
51. [51] Alexander, S., Hopewell, S., Hunter, S., Chouksey, A., Rituximab and desensitisation for patient with severe factor IX deficiency, inhibitors, and a history of anaphylaxis. J. Pediatr. Hematol. Oncol. 30 (2008), 93–95.
52. [52] Chuansumrit, A., Moonsup, Y., Sirachainan, N., Benjaponpitak, S., Suebsangad, A., Wongwerawattanakoon, P., The use of rituximab as an adjuvant for immune tolerance therapy in a haemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul. Fibrinolysis 19 (2008), 208–211.
53. [53] Fox, R.A., Neufeld, E.J., Bennett, C.M., Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 12 (2006), 218–222.
54. [54] Klarmann, D., Martinez Saguer, I., Funk, M.B., Knoefler, R., Von Hentig, N., Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 14 (2008), 44–49.
55. [55] Kobayashi, R., Sanoa, H., Suzukia, D., Kishimotoa, K., Yasudaa, K., Honjob, R., Hiroseb, M., Fujitab, S., Abeb, S., Kobayashia, K., Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor. Blood Coagul. Fibrinolysis 26 (2015), 580–582.
56. [56] Batorova, A., Morongova, A., Tagariello, G., Jankovicova, D., Prigancova, T., Horakova, J., Challenges in the Management of Hemophilia B with Inhibitor. Semin. Thromb. Hemost. 39:7 (2013), 767–771, 10.1055/s-0033-1356574.
57. [57] Gamerman, S., Singh, A.M., Makhija, M., Sharathkumar, A., Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab_ and desensitization therapy?. Haemophilia 19:6 (2013), e382–e385, 10.1111/hae.
58. [58] Mariani, G., Kroner, B., Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica 86 (2001), 1186–1193.
59. [59] Lenk, H., ITT Study Group, The German registry of immune tolerance treatment in haemophilia – 1999 update. Haematologica 85 (2000), 45–47.
60. [60] Rocino, A., Papa, M.L., Salerno, E., Capasso, F., Miraglia, E., de Basi, R., Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 7 (2001), 33–38.
61. [61] Berntorp, E., Immune tolerance induction: recombinant vs human-derived product. Haemophilia 7 (2001), 109–113.
62. [62] Collins, P.W., Chalmers, E., Hart, D.P., et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia. Br. J. Haematol. 160 (2013), 153–170 (4th edition).
63. [63] Evidence levels and grades of evidence. GRADE. Accessed in November 2015, http://www.bcshguidelines.com/BCSH_PROCESS/EVIDENCE_LEVELS_AND_GRADES_OF_RECOMMENDATION/43_GRADE.html.